← All trials
NCT04689191
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2020
- Primary completion
- May 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Dec 30, 2020
- Last posted
- Dec 30, 2020
- Enrollment
- 1280
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesSponsor investigator
- Government of ChinaOverall official - principal investigator
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.